Insmed (LTS:0JAV) Cyclically Adjusted Book per Share: $2.95 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JAV Insmed Inc LTS:0JAV
66 GF Score
Price $100.27
GF Value $185.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Cyclically Adjusted Book per Share?

Insmed LTS:0JAV +1.23% 66 Cyclically Adjusted Book per Share is $2.95 as of Mar. 2026. GuruFocus rates LTS:0JAV with a GF Score™ of 66/100 and a GF Value™ of $185.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Insmed's adjusted book value per share for the three months ended in Mar. 2026 was $3.255. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.95 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Insmed's average Cyclically Adjusted Book Growth Rate was -6.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -8.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Insmed was 5.60% per year. The lowest was -17.60% per year. And the median was -7.35% per year.

As of today (2026-08-05), Insmed's current stock price is $100.27. Insmed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $2.95. Insmed's Cyclically Adjusted PB Ratio of today is 33.99.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insmed was 67.68. The lowest was 2.56. And the median was 6.48.


Insmed  (LTS:0JAV) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insmed's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=100.27/2.95
=33.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insmed was 67.68. The lowest was 2.56. And the median was 6.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Insmed Cyclically Adjusted Book per Share Related Terms


Insmed Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Insmed's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Cyclically Adjusted Book per Share Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.49 4.01 3.54 3.19 2.98

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.05 3.13 3.06 2.98 2.95

LTS:0JAV vs INCY, BNTX, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Insmed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted PB Ratio falls into.


LTS:0JAV
66GF Score
Insmed Inc LTS:0JAV
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insmed's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.255/330.2130*330.2130
=3.255

Current CPI (Mar. 2026) = 330.2130.

Insmed Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.049 241.018 5.547
201609 3.520 241.428 4.814
201612 2.491 241.432 3.407
201703 1.960 243.801 2.655
201706 1.338 244.955 1.804
201709 5.502 246.819 7.361
201712 4.713 246.524 6.313
201803 5.675 249.554 7.509
201806 4.811 251.989 6.304
201809 3.780 252.439 4.945
201812 2.694 251.233 3.541
201903 1.858 254.202 2.414
201906 3.997 256.143 5.153
201909 3.404 256.759 4.378
201912 2.918 256.974 3.750
202003 2.300 258.115 2.942
202006 3.996 257.797 5.118
202009 3.507 260.280 4.449
202012 2.685 260.474 3.404
202103 1.952 264.877 2.433
202106 4.608 271.696 5.600
202109 4.265 274.310 5.134
202112 3.457 278.802 4.094
202203 1.004 287.504 1.153
202206 0.369 296.311 0.411
202209 -0.246 296.808 -0.274
202212 0.648 296.797 0.721
202303 -0.327 301.836 -0.358
202306 -1.091 305.109 -1.181
202309 -2.023 307.789 -2.170
202312 -2.243 306.746 -2.415
202403 -3.129 312.332 -3.308
202406 0.233 314.175 0.245
202409 2.703 315.301 2.831
202412 1.591 315.605 1.665
202503 0.545 319.799 0.563
202506 5.920 322.561 6.060
202509 4.448 324.800 4.522
202512 3.449 324.054 3.515
202603 3.255 330.213 3.255

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $2.95 mean?
Insmed (LTS:0JAV) has a Cyclically Adjusted Book per Share of $2.95 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insmed and its competitors.
Is Insmed's Cyclically Adjusted Book per Share too high?
Insmed's current Cyclically Adjusted Book per Share is $2.95. Overall, Insmed has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Cyclically Adjusted Book per Share compare to INCY and BNTX?
Insmed's Cyclically Adjusted Book per Share of $2.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insmed and its competitors. Insmed's current Cyclically Adjusted Book per Share is $2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (LTS:0JAV) is currently considered Possible Value Trap. The stock's GF Value™ is $185.40, compared to a current price of $100.27 — trading 45.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is $2.95. Insmed's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Insmed (LTS:0JAV), the current Cyclically Adjusted Book per Share is $2.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (LTS:0JAV) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $100.27 is trading 45.9% below its estimated GF Value™ of $185.40. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for LTS:0JAV:

  • Cyclically Adjusted Book per Share: $2.95
  • GF Value™: $185.40 vs. price of $100.27 (45.9% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
66GF Score

Get the complete analysis for LTS:0JAV

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.27
Price
$185.40
GF Value